The current member of the Sinfonia board of directors, Olof Larsson, is entering the operational role as the company’s CSO. Olof is replacing Johan Lundkvist who is continuing as COO. Olof’s prior experience as CSO for Eli Lilly Pain and Migraine makes him a key recruitment for the day-to-day work in the team with the immediate goal to strengthening the company’s pain portfolio and to leverage the clinical development of SB0101 (NeuRepair). “The company is currently in an expansive phase where Olof’s competence and drive is well suited to support the clinical development of SB0101 and to move the early portfolio into clinical development. I am very excited to have Olof onboard in our winning team”, says Lars Wahlberg, CEO.
